Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Identifieur interne : 000C84 ( Ncbi/Merge ); précédent : 000C83; suivant : 000C85Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Auteurs : Jorge L. Juncos [États-Unis] ; Vicki J. Roberts ; Marian L. Evatt ; Rita D. Jewart ; Colleen D. Wood ; Larry S. Potter ; Hann-Chang Jou ; Paul P. YeungSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Brief Psychiatric Rating Scale, Delusions (chemically induced), Delusions (diagnosis), Delusions (drug therapy), Dibenzothiazepines (adverse effects), Dibenzothiazepines (therapeutic use), Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Hallucinations (chemically induced), Hallucinations (diagnosis), Hallucinations (drug therapy), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (drug therapy), Psychoses, Substance-Induced (psychology).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Dibenzothiazepines, Levodopa.
- chemically induced : Delusions, Hallucinations.
- diagnosis : Delusions, Hallucinations, Psychoses, Substance-Induced.
- drug effects : Neurologic Examination.
- drug therapy : Delusions, Hallucinations, Parkinson Disease, Psychoses, Substance-Induced.
- psychology : Parkinson Disease, Psychoses, Substance-Induced.
- Aged, Aged, 80 and over, Brief Psychiatric Rating Scale, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuropsychological Tests.
Abstract
Twenty-nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24-week, single-center, open-label trial to assess the efficacy of quetiapine (12.5-400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24-week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well-tolerated antipsychotic in this population.
DOI: 10.1002/mds.10620
PubMed: 14743357
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003580
- to stream PubMed, to step Curation: 003580
- to stream PubMed, to step Checkpoint: 003341
Links to Exploration step
pubmed:14743357Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.</title><author><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L" last="Juncos">Jorge L. Juncos</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Emory University, Atlanta, Georgia 30329, USA. jjuncos@emory.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Department, Emory University, Atlanta, Georgia 30329</wicri:regionArea><wicri:noRegion>Georgia 30329</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J" last="Roberts">Vicki J. Roberts</name></author><author><name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L" last="Evatt">Marian L. Evatt</name></author><author><name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D" last="Jewart">Rita D. Jewart</name></author><author><name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D" last="Wood">Colleen D. Wood</name></author><author><name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S" last="Potter">Larry S. Potter</name></author><author><name sortKey="Jou, Hann Chang" sort="Jou, Hann Chang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name></author><author><name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P" last="Yeung">Paul P. Yeung</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14743357</idno><idno type="pmid">14743357</idno><idno type="doi">10.1002/mds.10620</idno><idno type="wicri:Area/PubMed/Corpus">003580</idno><idno type="wicri:Area/PubMed/Curation">003580</idno><idno type="wicri:Area/PubMed/Checkpoint">003341</idno><idno type="wicri:Area/Ncbi/Merge">000C84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.</title><author><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L" last="Juncos">Jorge L. Juncos</name><affiliation wicri:level="1"><nlm:affiliation>Neurology Department, Emory University, Atlanta, Georgia 30329, USA. jjuncos@emory.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Neurology Department, Emory University, Atlanta, Georgia 30329</wicri:regionArea><wicri:noRegion>Georgia 30329</wicri:noRegion></affiliation></author><author><name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J" last="Roberts">Vicki J. Roberts</name></author><author><name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L" last="Evatt">Marian L. Evatt</name></author><author><name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D" last="Jewart">Rita D. Jewart</name></author><author><name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D" last="Wood">Colleen D. Wood</name></author><author><name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S" last="Potter">Larry S. Potter</name></author><author><name sortKey="Jou, Hann Chang" sort="Jou, Hann Chang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name></author><author><name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P" last="Yeung">Paul P. Yeung</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Brief Psychiatric Rating Scale</term><term>Delusions (chemically induced)</term><term>Delusions (diagnosis)</term><term>Delusions (drug therapy)</term><term>Dibenzothiazepines (adverse effects)</term><term>Dibenzothiazepines (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Hallucinations (chemically induced)</term><term>Hallucinations (diagnosis)</term><term>Hallucinations (drug therapy)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Psychoses, Substance-Induced (psychology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Dibenzothiazepines</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Delusions</term><term>Hallucinations</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Delusions</term><term>Hallucinations</term><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Brief Psychiatric Rating Scale</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty-nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24-week, single-center, open-label trial to assess the efficacy of quetiapine (12.5-400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24-week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well-tolerated antipsychotic in this population.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14743357</PMID><DateCreated><Year>2004</Year><Month>01</Month><Day>26</Day></DateCreated><DateCompleted><Year>2004</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>29-35</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-nine elderly patients who failed treatment with clozapine, risperidone, or olanzapine entered this 24-week, single-center, open-label trial to assess the efficacy of quetiapine (12.5-400 mg/day) for psychosis in patients with Parkinson's disease (PD). Psychiatric, motor, and cognitive assessments were administered at baseline and at periodic intervals for 24 weeks. These included the Brief Psychiatric Rating Scale (BPRS), Neuropsychiatric Inventory (NPI), Unified Parkinson's Disease Rating Scale (UPDRS) and tests of intellectual functioning, attention, and memory. Repeated measures statistical analysis was used to assess change from baseline. The results revealed significant improvements in the 24-week BPRS total score and NPI psychosis subscale scores, with no decline in UPDRS total or motor subscale scores. There was also significant improvement in recall scores on cognitive measures. These results indicate that quetiapine may treat psychotic symptoms and improve cognition without worsening motor function in patients with PD, suggesting that quetiapine is an effective and well-tolerated antipsychotic in this population.</AbstractText><CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Juncos</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Neurology Department, Emory University, Atlanta, Georgia 30329, USA. jjuncos@emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Vicki J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Evatt</LastName><ForeName>Marian L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Jewart</LastName><ForeName>Rita D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Colleen D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Larry S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Jou</LastName><ForeName>Hann-Chang</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Yeung</LastName><ForeName>Paul P</ForeName><Initials>PP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5R01 AT00612-02</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>BGL0JSY5SI</RegistryNumber><NameOfSubstance UI="C069541">quetiapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010054">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003702">Delusions</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003987">Dibenzothiazepines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006212">Hallucinations</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011605">Psychoses, Substance-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14743357</ArticleId><ArticleId IdType="doi">10.1002/mds.10620</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Evatt, Marian L" sort="Evatt, Marian L" uniqKey="Evatt M" first="Marian L" last="Evatt">Marian L. Evatt</name><name sortKey="Jewart, Rita D" sort="Jewart, Rita D" uniqKey="Jewart R" first="Rita D" last="Jewart">Rita D. Jewart</name><name sortKey="Jou, Hann Chang" sort="Jou, Hann Chang" uniqKey="Jou H" first="Hann-Chang" last="Jou">Hann-Chang Jou</name><name sortKey="Potter, Larry S" sort="Potter, Larry S" uniqKey="Potter L" first="Larry S" last="Potter">Larry S. Potter</name><name sortKey="Roberts, Vicki J" sort="Roberts, Vicki J" uniqKey="Roberts V" first="Vicki J" last="Roberts">Vicki J. Roberts</name><name sortKey="Wood, Colleen D" sort="Wood, Colleen D" uniqKey="Wood C" first="Colleen D" last="Wood">Colleen D. Wood</name><name sortKey="Yeung, Paul P" sort="Yeung, Paul P" uniqKey="Yeung P" first="Paul P" last="Yeung">Paul P. Yeung</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Juncos, Jorge L" sort="Juncos, Jorge L" uniqKey="Juncos J" first="Jorge L" last="Juncos">Jorge L. Juncos</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:14743357
|texte= Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:14743357" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |